Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloroform. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL8192102 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8927142 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8196816 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL7542885 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL35119 | 1.00 | — | — | |
| Chloroform SCHEMBL7542887 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL7768433 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8927139 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL2118727 | 0.95 | — | — | |
| Chloroform SCHEMBL6974119 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220103-B1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | HAINAN DEZE DRUG RES CO LTD (CN) | 2015-04-08 | — | — | EP | disclosed |
| US-8334267-B2 | Mangiferin calcium salts, the method for its preparation and its use | HAINAN DEZE DRUG RESEARCH CO., LTD. (CN) | 2012-12-18 | — | — | US | disclosed |
| US-20100249046-A1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD (CN) | 2010-09-30 | — | — | US | disclosed |
| EP-2220103-A1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | Hainan Deze Drug Research Co., Ltd (CN) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065287-A1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | HAINAN DEZE DRUG RESEARCH CO., LTD (CN) | 2009-05-28 | — | — | WO | disclosed |
| WO-2008061480-A1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | HAINAN DEZE DRUG RESEARCH CO., LTD (CN) | 2008-05-29 | — | — | WO | disclosed |
| EP-0940387-B1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6069176-A | PHENYLETHANOLAMINE COMPOUNDS WITH A BETA-3 ADRENERGIC RECEPTOR STIMULATING EFFECT, USE AS A THERAPY FOR URINARY INCONTINENCE | MITSUBISHI-TOKYO PHARMACEUTICALS, INC. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0940387-A1 | PHENYLETHANOLAMINE COMPOUNDS USEFUL AS BETA3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME | TOKYO TANABE COMPANY LIMITED (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5629419-A | Process for preparing 4-mercaptopyrrolidine intermediate compounds and a process for their use in preparing carbapenem -2-em-3 carboxylic acids | TANABE SEIYAKU CO., LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0713866-A1 | Process for preparing 4-mercaptopyrrolidine compound | TANABE SEIYAKU CO., LTD. (JP) | 1996-05-29 | — | — | EP | disclosed |
| US-5399703-A | Antiallergens | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-03-21 | — | — | US | disclosed |
| EP-0308977-B1 | Anthracycline derivatives having inhibitory activity against reverse transcriptase of human immunodeficiency virus | ZAIDAN HOJIN BISEIBUTSU (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0536400-A1 | TETRAZOLE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-5003055-A | Anthracycline derivatives having inhibitory activity against reverse transcriptase of human immunodeficiency virus | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249046-A1 | NOVEL MANGIFERIN CALCIUM SALTS, THE METHOD FOR ITS PREPARATION AND ITS USE | ORAI1, SARAF, ITPR3 | TSHR 4024/4885ALDH1A1 4654/4885LMNA 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.